BPIFA1 and non-small cell lung carcinoma: Our study suggests that: (1) LUNX is a lung cancer-targetable tumor antigen during immunogenic senescence; (2) combining anti-LUNX antibody with immunogenic drugs that can induce senescence-associated translocation of LUNX to the plasma membrane might offer a new strategy to treat NSCLC.